Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14987614 | 0.94 | GLS (1.00) | GLS | |
| SCHEMBL21443368 | 0.94 | GLS (0.88) | GLS | |
| SCHEMBL14987561 | 0.94 | GLS (1.00) | GLS | |
| SCHEMBL20340835 | 0.93 | GLS (0.86) | GLS | |
| SCHEMBL14977106 | 0.93 | GLS (1.00) | GLS | |
| SCHEMBL14987469 | 0.91 | GLS (1.00) | GLS | |
| SCHEMBL21443372 | 0.91 | GLS (0.83) | GLS | |
| SCHEMBL14987033 | 0.90 | GLS (1.00) | GLS | |
| SCHEMBL14986999 | 0.89 | GLS (1.00) | GLS | |
| SCHEMBL15782608 | 0.89 | GLS (0.90) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 599 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION | 2025-06-05 | — | — | US | claimed |
| CN-119656315-A | Application of GLS1 inhibitor in relieving ulcerative colitis | 重庆医科大学 | 2025-03-21 | — | — | CN | claimed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| CN-119606870-A | Hydrogel and preparation method and application thereof | 重庆大学 | 2025-03-14 | — | — | CN | claimed |
| US-20250073321-A1 | Modulation of Oxidative Stress and Amino Acid Metabolism for the Treatment or Prevention of Diseases and Disorders | UNIV NEW YORK (US) | 2025-03-06 | — | — | US | claimed |
| EP-3956663-B1 | A METHOD OF PROFILING THE ENERGETIC METABOLISM OF A POPULATION OF CELLS | INST NAT SANTE RECH MED (FR) | 2025-02-12 | — | — | EP | claimed |
| EP-4489865-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | Ohio State Innovation Foundation (US) | 2025-01-15 | — | — | EP | claimed |
| CN-119215225-A | Medical modified titanium material and preparation method and application thereof | 重庆大学 | 2024-12-31 | — | — | CN | claimed |
| US-20240424004-A1 | COMBINATION OF TLR LIGANDS, COMPOUNDS LABELLING TUMORS FOR IMMUNE ATTACK, ANTI-CD40 ANTIBODIES AND INHIBITORS OF GLUTAMINE METABOLISM FOR TREATING CANCER | BIOCANIM A S (CZ) | 2024-12-26 | — | — | US | claimed |
| EP-4433056-A1 | COMBINATION OF TLR LIGANDS, COMPOUNDS LABELLING TUMORS FOR IMMUNE ATTACK, ANTI-CD40 ANTIBODIES AND INHIBITORS OF GLUTAMINE METABOLISM FOR TREATING CANCER | Biocanim A.s. (CZ) | 2024-09-25 | — | — | EP | claimed |
| WO-2022120187-A2 | METHOD OF DETERMINING RESISTANCE TO CHECKPOINT INHIBITOR THERAPIES | SHATTUCK LABS, INC. (US) | 2022-06-09 | — | — | WO | claimed |
| EP-3956663-A1 | A METHOD OF PROFILING THE ENERGETIC METABOLISM OF A POPULATION OF CELLS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-02-23 | — | — | EP | claimed |
| US-20210379087-A1 | COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2021-12-09 | — | — | US | claimed |
| EP-3892267-A1 | COMBINATORY TREATMENT FOR LYMPHOMA | Université de Paris (FR) | 2021-10-13 | — | — | EP | claimed |
| WO-2021183881-A1 | METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING GLUTAMINASE INHIBITOR-SENSITIVE CANCERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-16 | — | — | WO | claimed |
| CN-113347969-A | Composition for eliminating senescent cells | 维也纳自然资源与生命科学大学 | 2021-09-03 | — | — | CN | claimed |
| EP-3643305-A1 | COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS | Universität für Bodenkultur Wien (AT) | 2020-04-29 | — | — | EP | claimed |
| CN-106890184-B | Pharmaceutical composition of anti-tumor glutaminase inhibitor and tumor angiogenesis inhibitor and application thereof | 诺言医药科技(上海)有限公司 | 2019-06-25 | — | — | CN | claimed |
| US-20180028647-A1 | MODIFICATIONS OF THERAPEUTIC AGENTS FOR ENHANCED DELIVERY TO TARGET SITES | CLARIA ODIN LLC | 2018-02-01 | — | — | US | claimed |
| CN-106890184-A | Pharmaceutical composition of anti-tumor glutaminase inhibitor and tumor angiogenesis inhibitor and application thereof | 侯以琳 | 2017-06-27 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028647-A1 | MODIFICATIONS OF THERAPEUTIC AGENTS FOR ENHANCED DELIVERY TO TARGET SITES | PDK1, PC, PDK2 | GLS 20/4885 |
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | ACACB, SREBF2, FASN | GLS 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.